Prof. Xiaodong Wang 王晓东
Chief Physician, Professor
Department of Interventional Therapy, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Image-guided minimally invasive interventional oncology, including arterial chemoembolization, ablation, seed implantation, vertebroplasty, and management of tumor complications such as obstruction, bleeding, and fluid collections.
Dr. Wang holds an MD and serves as Deputy Director of the Interventional Therapy Department at Peking University Cancer Hospital. A former visiting scholar at Memorial Sloan Kettering Cancer Center, Dr. Wang received the CVIR Distinguished Contribution Award in 2014. Research focuses on interventional oncology, supported by National Natural Science Foundation grants.
Professional roles
- Member and Secretary, Tumor Intervention Professional Committee, China Anti-Cancer Association
- Member and Secretary, Tumor Intervention Professional Committee, Beijing Anti-Cancer Association
- Reviewer, CardioVascular and Interventional Radiology (CVIR)
- Reviewer, Journal of Vascular and Interventional Radiology (JVIR)
Name order: in Chinese the family name comes first (Wang Xiaodong). Papers usually list the name as Xiaodong Wang or Wang X.
Selected publications
62 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Hepatobiliary Surg Nutr, 2026 (senior author): Phase II trial of hepatic arterial infusion chemotherapy plus bevacizumab and toripalimab for advanced biliary tract cancers: efficacy, safety, and exploratory analysis. PubMed 41983220
- iScience, 2024 (senior author): Screening and molecular mechanism research on bile microRNAs associated with chemotherapy efficacy in perihilar cholangiocarcinoma. PubMed 39717085
- Front Oncol, 2024 (senior author): Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy. PubMed 39234395
- Front Cell Dev Biol, 2024 (senior author): Extrachromosomal circular DNA (eccDNA) characteristics in the bile and plasma of advanced perihilar cholangiocarcinoma patients and the construction of an eccDNA-related gene prognosis model. PubMed 38903532
- Sci Rep, 2024 (senior author): NLCECA score: a serum inflammatory-tumor biomarker score to predict survival of advanced perihilar cholangiocarcinoma after hepatic arterial infusion chemotherapy. PubMed 38395994
- Ther Adv Med Oncol, 2024 (senior author): Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers. PubMed 38282664
- Radiology, 2022 (senior author): Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial. PubMed 35103539
- Insights Imaging, 2022 (senior author): Signal enhancement ratio of CE-MRI: a potential biomarker of survival after hepatic arterial infusion chemotherapy in biliary tract cancers. PubMed 35286496
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion